U-NEURON BIOMEDICAL INC.
Update：2024/07/15
Industries
Main Industry
Biotechnology
Main Product/Service
State-level Storage Equipment and Technology
U-NEURON BIOMEDICAL is devoted to the development of stem cell isolation, storage and clinical applications. It owns the Patent on the Technology of Isolation and Culture of Amniotic Fluid Stem Cell, and has signed a service contract on the support of cell operation laboratory facilities and instruments with Bioresource Collection and Research Center; meanwhile, it has completed the pre-clinical trial for treatment of urinary incontinence with amniotic fluid stem cells with National Yang-Ming University. Recently, U-NEURON BIOMEDICAL has cooperated with Linkou Chang Gung Memorial Hospital on clinical trials of a rare disease – osteogenesis imperfecta (glass doll), and continues the research and development of the latest cell treatment and applications. Through continuous research, U-NEURON BIOMEDICAL carries out manufacturing that meets clinical specifications, creates new stem cell therapy technologies to fill current medical gaps, and popularizes stem cell technology and cell therapy products through professional technology development and medical research, creating real value of regenerative medicine and a better life for humankind.
U-NEURON BIOMEDICAL is devoted to the development of stem cell isolation, storage and clinical applications. It owns the Patent on the Technology of Isolation and Culture of Amniotic Fluid Stem Cell, and has signed a service contract on the support of cell operation laboratory facilities and instruments with Bioresource Collection and Research Center; meanwhile, it has completed the pre-clinical trial for treatment of urinary incontinence with amniotic fluid stem cells with National Yang-Ming University. Recently, U-NEURON BIOMEDICAL has cooperated with Linkou Chang Gung Memorial Hospital on clinical trials of a rare disease – osteogenesis imperfecta (glass doll), and continues the research and development of the latest cell treatment and applications. Through continuous research, U-NEURON BIOMEDICAL carries out manufacturing that meets clinical specifications, creates new stem cell therapy technologies to fill current medical gaps, and popularizes stem cell technology and cell therapy products through professional technology development and medical research, creating real value of regenerative medicine and a better life for humankind.
Founded Year
2015
Unified Business No.
54867417
Status
Active
Number of Employees
30
Total Paid-in
Capital
395,500,000 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2023)
Exclusive content for members
Members-only content. Please log in to access.
Introduction
U-NEURON GROUP is committed to advancing the real value of regenerative medicine by popularizing cell therapy and related products to improve human life. The group consists of U-NEURON BIOMEDICAL CO., LTD., specializing in cell therapy technology R&D, and UAF BIOMEDICAL, which owns ExoCare, a leading brand in medical aesthetics.
Chairman’s Message
U-NEURON GROUP aims to develop innovative cell therapy technologies and become Taiwan’s first professional amniotic fluid stem cell storage organization. By leveraging the group’s expertise, the company seeks to address unmet medical needs through advanced R&D, offer effective treatment options, and build accessible, trustworthy brands in medical beauty and regenerative medicine.
Expertise in Amniotic Fluid Stem Cells
Founded in 2015, U-NEURON BIOMEDICAL focuses on stem cell research and clinical applications. The company collaborates with top medical and academic institutions including the Bioresource Collection and Research Center, National Yang-Ming University, Taipei Veterans General Hospital, Cathay General Hospital, Linkou Chang Gung Memorial Hospital, and China Medical University Hospital.
Currently, the company’s main work centers on stem cell storage and clinical trials. It has submitted an application for a Phase II clinical trial using autologous stem cell transplantation to treat stroke. Notably, U-NEURON BIOMEDICAL is the first company in Taiwan to receive a U.S. patent for the culture and isolation of amniotic fluid stem cells.
Chairman’s Message
U-NEURON GROUP aims to develop innovative cell therapy technologies and become Taiwan’s first professional amniotic fluid stem cell storage organization. By leveraging the group’s expertise, the company seeks to address unmet medical needs through advanced R&D, offer effective treatment options, and build accessible, trustworthy brands in medical beauty and regenerative medicine.
Expertise in Amniotic Fluid Stem Cells
Founded in 2015, U-NEURON BIOMEDICAL focuses on stem cell research and clinical applications. The company collaborates with top medical and academic institutions including the Bioresource Collection and Research Center, National Yang-Ming University, Taipei Veterans General Hospital, Cathay General Hospital, Linkou Chang Gung Memorial Hospital, and China Medical University Hospital.
Currently, the company’s main work centers on stem cell storage and clinical trials. It has submitted an application for a Phase II clinical trial using autologous stem cell transplantation to treat stroke. Notably, U-NEURON BIOMEDICAL is the first company in Taiwan to receive a U.S. patent for the culture and isolation of amniotic fluid stem cells.
